Vivet Therapeutics Announces 4 Presentations During the 2022 American Society Of Gene And Cell Therapy Annual Meeting
Vivet Therapeutics, a clinical-stage biotech company dedicated to developing gene therapy
Vivet presenting during 2022 ARM Meeting on the Med in Barcelona
Vivet Therapeutics BD Director, Thomas Daniel-Robin
VIVET ATTENDING 2021 WORLD ORPHAN DRUG CONGRESS EUROPE IN BARCELONA
Vivet Therapeutics CEO, Jean-Philippe Combal, will be participating to a panel during 2021 World Orphan Drug Congress Europe in Barcelona (Nov 15-18).
Vivet Therapeutics awarded with the Prix Galien MedStartup in New York
Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing Or Underserved Populations Worldwide”.
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
Vivet CDO, Anne Douar, presenting during SFTCG webinar on Gene Therapy for Wilson Disease
Vivet CDO, Anne Douar, will be presenting
GATEWAY clinical trial for Wilson Disease has now its website
Wilson Disease is a rare, progressive genetic disorder that causes excess copper to be stored in the body.
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease
Learn how gene therapy aims to target the cause of Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!